Off the wire
• Overnight Saudi-led airstrike hits diary factory in Yemen, 37 killed  • Vehicles are top polluter in Beijing: official  • Singapore kicks off World Intellectual Property Day Celebrations  • Gold price closes higher in Hong Kong  • Mauritius economy forecasted to grow at 4.1 pct in 2015  • Benin in bid to end social unrest in public sector  • World Bank gives Cote d'Ivoire 50 mln USD for youth employment  • Chinese firm offers scholarships to students of Lome University  • Maldives gov't attempts to evacuate three students in war-torn Yemen  • Sri Lanka's inflation hits all time low in March  
You are here: 　 Home

Liberia-U.S. team plans study of Ebola survivors

Xinhua, April 1, 2015 Adjust font size:

The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), a Liberia-U.S. research team, plans to launch a natural history study of Ebola survivors for better understanding of the after-effects of Ebola virus disease.

According to a PREVAIL statement, four sites in Monrovia and locations in the United States may begin enrollment into this study in the coming months.

The study is pending regulatory review and approval, according to the statement issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

NIAID conducts and supports research at NIH, throughout the United States and worldwide.

It carries out study of the causes of infectious and immune- mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.

PREVAIL is currently conducting trials of two experimental Ebola vaccines in Liberia with more than 600 people in Liberia participating in the first stage and about 1,500 volunteers are expected to enroll in Phase Two.

The trial, which began on Feb. 2, 2015 in Monrovia, is testing the safety and efficacy of the cAd3-EBOZ candidate vaccine co- developed by NIAID scientists and GlaxoSmithKline, and the VSV- ZEBOV candidate vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corporation and Merck. Endi